Brokerages Set EXACT Sciences Co. (NASDAQ:EXAS) Price Target at $109.40

Share on StockTwits

EXACT Sciences Co. (NASDAQ:EXAS) has been assigned an average recommendation of “Buy” from the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $110.90.

A number of equities analysts have commented on the company. BidaskClub cut Ames National from a “hold” rating to a “sell” rating in a research note on Wednesday. Canaccord Genuity upped their price target on Ideagen from GBX 170 ($2.22) to GBX 180 ($2.35) and gave the company a “buy” rating in a report on Wednesday. Craig Hallum upped their price objective on 1-800-Flowers.Com from $26.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. BTIG Research upped their price objective on Apple to $234.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Monday, July 8th.

NASDAQ:EXAS traded up $1.16 on Friday, reaching $117.50. 30,357 shares of the stock traded hands, compared to its average volume of 1,134,850. The stock has a market capitalization of $14.99 billion, a price-to-earnings ratio of -86.07 and a beta of 1.64. The firm has a 50 day moving average of $112.44. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13. EXACT Sciences has a 1-year low of $47.78 and a 1-year high of $121.98.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Tuesday, April 30th. The medical research company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.01). The company had revenue of $162.00 million during the quarter, compared to the consensus estimate of $153.07 million. EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. The firm’s revenue for the quarter was up 79.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.33) EPS. On average, sell-side analysts predict that EXACT Sciences will post -2.18 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in EXAS. Grandview Asset Management LLC purchased a new stake in EXACT Sciences during the 2nd quarter worth approximately $224,000. Oakbrook Investments LLC boosted its holdings in shares of EXACT Sciences by 12.1% during the 2nd quarter. Oakbrook Investments LLC now owns 3,475 shares of the medical research company’s stock worth $410,000 after purchasing an additional 375 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $4,840,000. NEXT Financial Group Inc acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $50,000. Finally, IFM Investors Pty Ltd acquired a new position in shares of EXACT Sciences during the 2nd quarter worth approximately $961,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: What is a bull market?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.